Suchen
Genmab A/S
GMABZur Watchlist hinzufügen
26.020USD
-0.100-0.38%
Handelsschluss 06/29, 16:00（ET）Kurse um 15 Minuten verzögert
16.38BMarktkapitalisierung
19.60KGV TTM
mehr Informationen über Genmab A/S Unternehmen
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/S Informationen
BörsenkürzelGMAB
Name des UnternehmensGenmab A/S
IPO-datumOct 01, 2000
CEOVan De Winkel (Jan G.J)
Anzahl der mitarbeiter2682
WertpapierartDepository Receipt
GeschäftsjahresendeOct 01
AddresseCarl Jacobsens Vej 30
StadtVALBY
BörseNASDAQ OMX - NASDAQ BASIC
LandDenmark
Postleitzahl2500
Telefon4570202728
Websitehttps://www.genmab.com/
BörsenkürzelGMAB
IPO-datumOct 01, 2000
CEOVan De Winkel (Jan G.J)
Führungskräfte von Genmab A/S
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Genmab A/S?
Die fünf größten Anteilseigner von Genmab A/S sind: Dr. Jan G.J. Van De Winkel, Ph.D.
Wie viele Institutionen halten Anteile an Genmab A/S (GMAB)?
Mit Stand vom 2026Q1 halten 564 Institutionen Anteile an Genmab A/S, mit einem Gesamtmarktwert von etwa 74.31M, was 12.10% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2989185.00 gestiegen.
Was ist die größte Einnahmequelle von Genmab A/S?
Am 2026Q1 erzielte das Geschäft mit Royalties für Genmab A/S den höchsten Umsatz in Höhe von 3.10B, was 83.39% des Gesamtumsatzes entspricht.
